Fibroblast Growth Factor-2 Inhibitor, NSC37204 - Calbiochem

A small molecule, compound that is shown to compete with the binding domain of TSP-1 against angiogenic factor FGF-2 (IC₅₀ = 1.3 µM) in a dose-dependent manner and prevents the binding of FGF-2 to HSPG on endothelial cells (IC₅₀ = 24.0 ± 6.9 µM), in vitro. It also demonstrates anti-growth properties in FGF-2-induced, but not serum-induced, endothelial cells (IC₅₀ = 20.3 µM ± 5.9 µM). In CAM assays in vivo, where angiogenesis is induced by FGF-2 embedded in gelatin sponges, the presence of the small molecule (0.5 µg) reduces the mean number of blood vessels entering the sponge from 26 ±4 (FGF-2 alone) to 10 ± 2 (FGF-2 + NSC37203).

A small molecule, compound that is shown to compete with the binding domain of TSP-1 against angiogenic factor FGF-2 (IC₅₀ = 1.3 µM) in a dose-dependent manner and prevents the binding of FGF-2 to HSPG on endothelial cells (IC₅₀ = 24.0 ±6.9 µM), in vitro. It also demonstrates anti-growth properties in FGF-2-induced, but not serum-induced, endothelial cells (IC₅₀ = 20.3 µM ±5.9 µM). In CAM assays in vivo, where angiogenesis is induced by FGF-2 embedded in gelatin sponges, the presence of the small molecule (0.5 µg) reduces the mean number of blood vessels entering the sponge from 26 ±4 (FGF-2 alone) to 10 ±2 (FGF-2 + NSC37203).

Colombo, G., et al. 2010. J. Biol. Chem.285, 8733.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Toxicity: Standard Handling (A)